126 related articles for article (PubMed ID: 8400566)
1. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis.
Tanimoto A; Kreft BP; Baba Y; Zhao L; Finn JP; Compton CC; Stark DD
J Magn Reson Imaging; 1993; 3(5):786-93. PubMed ID: 8400566
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
3. Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Finn JP; Stark DD
J Magn Reson Imaging; 1994; 4(3):337-42. PubMed ID: 8061431
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model.
Marzola P; Maggioni F; Vicinanza E; Daprà M; Cavagna FM
J Magn Reson Imaging; 1997; 7(1):147-52. PubMed ID: 9039606
[TBL] [Abstract][Full Text] [Related]
5. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP.
Coley BD; Mattrey RF; Baker KG; Peterson T; Burgan AR
J Magn Reson Imaging; 1995; 5(1):11-6. PubMed ID: 7696800
[TBL] [Abstract][Full Text] [Related]
6. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky NM; Weinreb JC
Magn Reson Q; 1992 Sep; 8(3):156-68. PubMed ID: 1390058
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
[TBL] [Abstract][Full Text] [Related]
8. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity.
Bernardino ME; Young SW; Lee JK; Weinreb JC
Radiology; 1992 Apr; 183(1):53-8. PubMed ID: 1549694
[TBL] [Abstract][Full Text] [Related]
9. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
Reimer P; Schneider G; Schima W
Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
[TBL] [Abstract][Full Text] [Related]
10. Gadobenate dimeglumine as an intrabiliary contrast agent: comparison with mangafodipir trisodium with respect to non-dilated biliary tree depiction.
Lim JS; Kim MJ; Jung YY; Kim KW
Korean J Radiol; 2005; 6(4):229-34. PubMed ID: 16374080
[TBL] [Abstract][Full Text] [Related]
11. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
12. Adrenal gland enhancement at MR imaging with Mn-DPDP.
Mitchell DG; Outwater EK; Matteucci T; Rubin DL; Chezmar JL; Saini S
Radiology; 1995 Mar; 194(3):783-7. PubMed ID: 7862979
[TBL] [Abstract][Full Text] [Related]
13. A segmental hyperintensity area in the liver shown by delayed MR images with Mn-DPDP.
Suto Y; Weinreb JC; Rofski NM
J Comput Assist Tomogr; 1996; 20(4):647-9. PubMed ID: 8708073
[TBL] [Abstract][Full Text] [Related]
14. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate.
Young SW; Simpson BB; Ratner AV; Matkin C; Carter EA
Magn Reson Med; 1989 Apr; 10(1):1-13. PubMed ID: 2502699
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of fatty liver with MR imaging.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
[TBL] [Abstract][Full Text] [Related]
16. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Federle MP; Peterson MS; Oliver JH; Davis PL; Confer SR
Radiology; 1996 Feb; 198(2):567-72. PubMed ID: 8596867
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
18. Soluble-type hepatobiliary contrast agents for MR imaging.
de Haën C; Gozzini L
J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
[No Abstract] [Full Text] [Related]
19. MRI contrast media for the liver. Efficacy in conditions of acute biliary obstruction.
Leander P; Golman K; Klaveness J; Holtz E; Olsson M; Leunbach I
Invest Radiol; 1990 Oct; 25(10):1130-4. PubMed ID: 2127772
[TBL] [Abstract][Full Text] [Related]
20. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.
Vogl TJ; Hamm B; Schnell B; McMahon C; Branding G; Lissner J; Wolf KJ
J Magn Reson Imaging; 1993; 3(1):51-8. PubMed ID: 8381314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
